DBV Technologies (DBVT) Enterprise Value (2014 - 2026)
DBV Technologies (DBVT) reported Enterprise Value of -$229.2 million for Q1 2026, down 1668.25% year-over-year from $14.6 million in Q1 2025, and down 18.02% on a QoQ basis from -$194.2 million in Q4 2025.
DBV Technologies (DBVT) has 13 years of Enterprise Value data on file, last reported at -$229.2 million in Q1 2026.
- Quarterly Enterprise Value fell 1668.25% year-over-year to -$229.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$229.2 million (down 1668.25% YoY) and the FY2025 annual result came in at -$194.2 million, down 498.35% from the prior year.
- Enterprise Value fell to -$229.2 million in Q1 2026 per DBVT's latest filing, from -$194.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$13.0 million in Q1 2025 and bottomed at -$248.0 million in Q2 2022.
- The 5-year median for Enterprise Value is -$141.4 million (2023), against an average of -$132.7 million.
- The widest annual swing landed in 2025, when Enterprise Value surged 87.23%; it then plunged 1668.25% in 2026.
- Tracing DBVT's Enterprise Value over 5 years: stood at -$209.2 million in 2022, then soared by 32.42% to -$141.4 million in 2023, then surged by 77.04% to -$32.5 million in 2024, then slumped by 498.35% to -$194.2 million in 2025, then declined by 18.02% to -$229.2 million in 2026.
- Per Business Quant, the three latest DBVT Enterprise Value figures stand at -$229.2 million (Q1 2026), -$194.2 million (Q4 2025), and -$69.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | -229.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -229.20 Mn |
| Dec 31, 2025 | -194.20 Mn |
| Sep 30, 2025 | -69.84 Mn |
| Jun 30, 2025 | -103.20 Mn |
| Mar 31, 2025 | -12.96 Mn |
| Dec 31, 2024 | -32.46 Mn |
| Sep 30, 2024 | -46.40 Mn |
| Jun 30, 2024 | -66.21 Mn |
| Mar 31, 2024 | -101.53 Mn |
| Dec 31, 2023 | -141.37 Mn |
| Sep 30, 2023 | -149.14 Mn |
| Jun 30, 2023 | -173.96 Mn |
| Mar 31, 2023 | -192.29 Mn |
| Dec 31, 2022 | -209.19 Mn |
| Sep 30, 2022 | -212.67 Mn |
| Jun 30, 2022 | -247.97 Mn |
| Mar 31, 2022 | -74.10 Mn |
| Dec 31, 2021 | -77.30 Mn |
| Sep 30, 2021 | -98.20 Mn |
| Jun 30, 2021 | -125.50 Mn |
| Mar 31, 2021 | -152.46 Mn |
| Dec 31, 2020 | -196.35 Mn |
| Sep 30, 2020 | -221.40 Mn |
| Jun 30, 2020 | -248.77 Mn |
| Mar 31, 2020 | -287.44 Mn |
| Dec 31, 2019 | -190.41 Mn |
| Sep 30, 2019 | -136.61 Mn |
| Jun 30, 2019 | -120.53 Mn |
| Dec 31, 2018 | -140.13 Mn |
| Sep 30, 2018 | -160.37 Mn |
| Jun 30, 2018 | -164.55 Mn |
| Dec 31, 2017 | -162.34 Mn |
| Jun 30, 2017 | -218.46 Mn |
| Dec 31, 2016 | -276.92 Mn |
| Jun 30, 2016 | -326.26 Mn |
| Dec 31, 2015 | -354.46 Mn |
| Jun 30, 2015 | -115.53 Mn |
| Dec 31, 2014 | -143.17 Mn |